TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33947729
Drug: Episodic adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Episodic adalimumab monotherapy (24 weeks)
Study: 32423429
Drug: Onkyeong-tang (OKT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onkyeong-tang (OKT), 3 g orally three times per day for 8 weeks
Study: 32423429
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 g orally three times per day for 8 weeks
Study: 32756091
Drug: Liuwei Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liuwei Dihuang pills (LDP)
Study: 34820771
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day rosuvastatin for 6 months
Study: 36272926
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy combined with nutritional supplementation (Ex + Nutr; n = 29)
Study: 36272926
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy alone (Ex; n = 29)
Study: 33899934
Drug: Various dosing
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various dosing regimen optimization strategies for ADCs including body weight cap dosing, treatment duration capping, dose schedule adjustments, response-guided dosing recommendations, and randomized dose-finding.
Study: 32488891
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A (BTX-A) injection and a home-based exercise program
Study: 34167656
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (5 daily sessions, 1mA for 20min over parieto-occipital regions)
Study: 34494088
Drug: Lactulose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (20 g)
Study: 33933751
Drug: Intravenous fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fish oil (IV-FO)
Study: 32772873
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (50 mg)
Study: 32585077
Drug: Differentiated service
Normalized name: SYRINGE SERVICES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differentiated service delivery (DSD) model implementation including repeat prescription collection strategies (RPCS)
Study: 32585077
Drug: Enhanced counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced counselling and tracing patients lost-to-follow-up for patients not stable on treatment
Study: 34738278
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia + LLLT (diode laser: 810 nm; continuous mode; 0.3W; 20 s; 69 J/cm2)
Study: 34738278
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia + LLLT
Study: 35905275
Drug: Chlorhexidine digluconate
Normalized name: Chlorhexidine digluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine digluconate lozenges
Study: 33477165
Drug: Reflexology applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reflexology applied for 20 min (10 min for each foot) twice a day with 8-hour intervals on the first and second days after CS
Study: 33835715
Drug: Vancomycin trough
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin trough concentration (VTC) less than 10 mg/L
Study: 33835715
Drug: Vancomycin trough
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin trough concentration (VTC) 10–15 mg/L
Study: 33835715
Drug: Vancomycin trough
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin trough concentration (VTC) 15–20 mg/L
Study: 33835715
Drug: Vancomycin trough
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin trough concentration (VTC) greater than 20 mg/L
Study: 97266229
Drug: Insulin administration
Normalized name: insulin administration supplies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin administration during hyperglycaemic conditions
Study: 97266229
Drug: Insulin administration
Normalized name: insulin administration supplies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin administration during normoglycaemic conditions
Study: 97266229
Drug: Insulin administration
Normalized name: insulin administration supplies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin administration in normal subjects
Study: 35791476
Drug: Garlic (KWAI)
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic (KWAI) 300 mg daily in doses of 0.3g, 0.6g, 0.9g, 1.2g, and 1.5g for 24 weeks
Study: 35791476
Drug: Simvastatin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (standard lipid-lowering agent)
Study: 35333803
Drug: Anal bulking
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anal bulking agent with polyacrylate‐polyalcohol copolymer particles
Study: 32448336
Drug: Intravenous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine (0.02 mg/kg)
Study: 32448336
Drug: Intramuscular buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular buprenorphine (0.02 mg/kg)
Study: 32448336
Drug: Subcutaneous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous buprenorphine (0.02 mg/kg)
Study: 32448336
Drug: Carprofen (4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (4.4 mg/kg SC)
Study: 34453013
Drug: CHO (Carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (Carbohydrate drink 1.2 g kg‐1 2 hr‐1)
Study: 34453013
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + PRO (Carbohydrate drink with whey protein concentrate 0.3 g kg‐1 2 hr‐1)
Study: 34453013
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + PROH (Carbohydrate drink with whey protein hydrolysate 0.3 g kg‐1 2 hr‐1)
Study: 32620104
Drug: Melissa officinalis
Normalized name: melissa officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melissa officinalis (2 g)
Study: 32620104
Drug: Lavandula angustifolia
Normalized name: Lavandula Angustifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavandula angustifolia (2 g)
Study: 34424165
Drug: Ring Screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ring Screening (RS) with niclosamide treatment
Study: 34424165
Drug: Ring Treatment
Normalized name: RING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ring Treatment (RT) with presumptive niclosamide treatment
Study: 34424165
Drug: Mass Treatment
Normalized name: Masse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Treatment (MT) with niclosamide treatment every 6 months
Study: 36107229
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (ferric derisomaltose)
Study: 36107229
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous fumarate)
Study: 32912462
Drug: UFR-guided hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFR-guided hydration (hydration controlled by the RenalGuard System to reach UFR ≥300 ml/h)
Study: 32912462
Drug: LVEDP-guided hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVEDP-guided hydration (normal saline infusion rate adjusted according to LVEDP)
Study: 33355918
Drug: Proton beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton beam therapy
Study: 35147535
Drug: Integrated Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Care Pathway including a sequential pharmacological algorithm and structured behavioral interventions
Study: 33105345
Drug: Pelvic radiation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiation therapy (RT)
Study: 33105345
Drug: No pelvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pelvic radiation therapy (no-RT)
Study: 32818949
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) intravenous infusion
Study: 32660261
Drug: Scapular exercise
Normalized name: Haemophilus capsular oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scapular exercise with cognitive functional therapy
Study: 35861974
Drug: Intravitreal rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal rt‐PA injection before vitrectomy
Study: 36127726
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100 µg/25 µg once daily for 14 days
Study: 33513483
Drug: 10 ng/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ng/L TPT + 0.4% FOS
Study: 33513483
Drug: 10 ng/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ng/L TPT + 0.8% FOS
Study: 33513483
Drug: 10 ng/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ng/L TPT
Study: 33860672
Drug: Midodrine 10
Normalized name: midodrine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 10 mg three-times a day for 5 days
Study: 35973473
Drug: Sporopollenin exine
Normalized name: oxine
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sporopollenin exine capsules (SpECs) containing vitamin D
Study: 33774956
Drug: Oral omega
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral omega 3 in standard dose along with oral isotretinoin
Study: 33774956
Drug: Placebo along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo along with oral isotretinoin
Study: 36149730
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (Group 1)
Study: 36149730
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy and mobile health agent (Group 2)
Study: 36149730
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health agent (Group 3)
Study: 36149730
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group 4)
Study: 33430476
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (therapy on dry land and aquatic therapy with Ai Chi)
Study: 33430476
Drug: Dry land
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dry land therapy (control group)
Study: 35042175
Drug: Intravaginal (IV)
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal (IV) PGE2 (2 mg)
Study: 35042175
Drug: Intracervical (IC)
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical (IC) PGE2 (0.5 mg)
Study: 35918438
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral serratus anterior plane block (SAPB) with 3 mg/kg 0.25% ropivacaine
Study: 35918438
Drug: Incision infiltration
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision infiltration (II) with 3 mg/kg 0.75% ropivacaine
Study: 35246048
Drug: NTI (Nociceptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTI (Nociceptive Trigeminal Inhibition) oral device
Study: 34081923
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine recipients
Study: 34081923
Drug: Bivalent HPV
Normalized name: HPV, bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent HPV vaccine recipients
Study: 33590594
Drug: Vibration stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration stimulation during intramuscular injection
Study: 33590594
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular injection without vibration stimulation
Study: 35725523
Drug: Budesonide 256
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 256 µg/day
Study: 34132695
Drug: Early prehospital
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early prehospital tranexamic acid (TXA) administered within 1 hour from time of injury
Study: 34132695
Drug: Delayed prehospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed prehospital tranexamic acid (TXA) administered beyond 1 hour from time of injury
Study: 32706639
Drug: Neoadjuvant chemohormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemohormonal therapy (CHT) with androgen deprivation plus docetaxel (75 mg/m2 every 3 weeks for 6 cycles) and radical prostatectomy (RP)
Study: 36041750
Drug: Sotatercept 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept 0.3 or 0.7 mg·kg‐1 (placebo-crossed group)
Study: 33436053
Drug: Jin’s three‐needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin’s three‐needle acupuncture (JTN) combined with mirror therapy (MT)
Study: 35240478
Drug: Emergency medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency medicine journals
Study: 33962499
Drug: Herbal supplement
Normalized name: LYDIA PINKHAM Herbal Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal supplement (Combi-5) taken along with vitamin C and Zinc supplements
Study: 35565744
Drug: 8% trehalose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% trehalose solution
Study: 35565744
Drug: 6% trehalose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% trehalose solution
Study: 35565744
Drug: 4% trehalose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% trehalose solution
Study: 35565744
Drug: 8% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% glucose solution
Study: 34520431
Drug: Targeted intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted intravenous albumin infusions
Study: 32686874
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg TCT daily
Study: 32686874
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg TCT daily
Study: 33440964
Drug: Local oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local oxygen therapy (LOT)
Study: 35276840
Drug: Zinc dispersible
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc dispersible tablet
Study: 32227161
Drug: Used a
Normalized name: Sympathomimetics used as decongestants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used a placebo analgesic cream
Study: 32227161
Drug: Merely possessed
Normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL LIPSTICK [Lipshade SPF 30 Obsessed]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merely possessed a placebo analgesic cream
Study: 32227161
Drug: Possessed and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possessed and used a placebo analgesic cream
Study: 32227161
Drug: Possessed a
Normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL LIPSTICK [Lipshade SPF 30 Obsessed]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possessed a sham cream
Study: 32890015
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion (50 mg kg-1 followed by 15 mg kg-1 h-1)
Study: 33677113
Drug: Immediate spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate spa therapy (18 days)
Study: 33677113
Drug: Delayed spa
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed spa therapy (after 6 months)
Study: 32331062
Drug: Dasotraline (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline (4, 6, and 8 mg/d)
Study: 35137935
Drug: Melatonin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (300 mg capsule)
Study: 32020523
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day zinc supplement
Study: 36018353
Drug: Biological xenograft
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological xenograft surgery
Study: 33100020
Drug: Insulin medications
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin medications
Study: 33100020
Drug: Non-insulin medications
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin medications
Study: 33737439
Drug: Medication changes
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication changes
Study: 34075612
Drug: P218 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: P218 (up to 1000 mg)
Study: 34058250
Drug: Group 1A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1A: 2 sizes larger than the IABF with a 4% taper
Study: 34058250
Drug: Group 1B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1B: 2 sizes larger than the IABF with a 6% taper
Study: 34058250
Drug: Group 2A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2A: 3 sizes larger than the IABF with a 4% taper
Study: 34058250
Drug: Group 2B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2B: 3 sizes larger than the IABF with a 6% taper
Study: 34941083
Drug: MNF scoring
Normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNF scoring system (derived from clinical risk factors including female gender, age > 60 years, WBC ≤5000/mm3, WBC ≥35,000/mm3, creatinine ≥1.6 mg/dL, pulse rate >130/min)
Study: 32705205
Drug: Conventional phacoemulsification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional phacoemulsification treatment (CPCS) + DEX/TOB
Study: 32451933
Drug: Sulodexide 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide 500 lipasemic units (LSUs) twice daily
Study: 32451933
Drug: Sulodexide 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide 250 LSU twice daily + indistinguishable placebo
Study: 35075679
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (esomeprazole 20 mg 4 times daily and amoxicillin 1000 mg 3 times daily for 14 days)
Study: 35075679
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, all twice daily for 14 days)
Study: 34032663
Drug: Neostigmine (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.07 mg/kg to a maximum of 5 mg)
Study: 33296786
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block with 30 ml of 0.2% ropivacaine
Study: 33296786
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 ml of 0.9% saline)
Study: 35991210
Drug: LY3127804 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3127804 (20 mg/kg)
Study: 34463432
Drug: Islatravir (MK-8591)
Normalized name: vitamin MK 7
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir (MK-8591) single doses (5 mg to 400 mg)
Study: 34463432
Drug: Islatravir (MK-8591)
Normalized name: vitamin MK 7
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir (MK-8591) multiple doses (10 mg, 30 mg, 100 mg)
Study: 34463432
Drug: Islatravir (MK-8591)
Normalized name: vitamin MK 7
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir (MK-8591) single doses (greater than or equal to 5 mg)
Study: 32312713
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg SDG/day (Brevail)
Study: 34693932
Drug: De Simone
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De Simone Formulation Probiotic (DSFP; 'Visbiome') for 48 weeks
Study: 35829773
Drug: Sodium hypochlorite
Normalized name: Sodium hypochlorite
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium hypochlorite gel (NaOCl)
Study: 35829773
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel (CHX)
Study: 33983371
Drug: 3-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day regimen of Pyronaridine-artesunate (180:60 mg)
Study: 33983371
Drug: 2-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-day regimen of Pyronaridine-artesunate (180:60 mg)
Study: 33983371
Drug: 1-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-day regimen of Pyronaridine-artesunate (180:60 mg)
Study: 34229742
Drug: Curcumin-piperine capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin-piperine capsules (3 capsules/day; 1500 mg curcumin and 15 mg piperine daily) for 7 days
Study: 34229742
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (3 capsules/day; 1515 mg maltodextrin daily) for 7 days
Study: 34229742
Drug: Curcumin-piperine capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin-piperine capsules
Study: 36332652
Drug: Combination HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HIV prevention package including immediate ART initiation
Study: 36332652
Drug: Combination HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HIV prevention package excluding immediate ART initiation
Study: 32343994
Drug: Electronic cigarette
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic cigarette (nicotine concentration of 12 mg/ml)
Study: 33076964
Drug: Intramuscular 120
Normalized name: Intramuscular Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 120 mg methylprednisolone followed by methotrexate (increasing dose to 25 mg/week orally)
Study: 33076964
Drug: Placebo (injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (injection and tablets)